These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 24780461)

  • 41. [The effects of VEGF-R inhibitor on podocytopathy of rats with type I diabetic nephropathy].
    Wang S; Li Y; Huang YJ
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Sep; 27(9):1003-6. PubMed ID: 21906476
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Natural history and clinical characteristics of CKD in type 1 and type 2 diabetes mellitus.
    Marshall SM
    Adv Chronic Kidney Dis; 2014 May; 21(3):267-72. PubMed ID: 24780454
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy.
    Elseweidy MM; Elswefy SE; Younis NN; Zaghloul MS
    Exp Biol Med (Maywood); 2013 Aug; 238(8):881-8. PubMed ID: 23970406
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy.
    Fechete R; Heinzel A; Perco P; Mönks K; Söllner J; Stelzer G; Eder S; Lancet D; Oberbauer R; Mayer G; Mayer B
    Proteomics Clin Appl; 2011 Jun; 5(5-6):354-66. PubMed ID: 21491608
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early urinary and plasma biomarkers for experimental diabetic nephropathy.
    Alter ML; Kretschmer A; Von Websky K; Tsuprykov O; Reichetzeder C; Simon A; Stasch JP; Hocher B
    Clin Lab; 2012; 58(7-8):659-71. PubMed ID: 22997966
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Urinary biomarkers involved in type 2 diabetes: a review.
    Matheson A; Willcox MD; Flanagan J; Walsh BJ
    Diabetes Metab Res Rev; 2010 Mar; 26(3):150-71. PubMed ID: 20222150
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Urinary Proteomics for Diagnosis and Monitoring of Diabetic Nephropathy.
    Currie G; Delles C
    Curr Diab Rep; 2016 Nov; 16(11):104. PubMed ID: 27658932
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Markers of and risk factors for the development and progression of diabetic kidney disease.
    Macisaac RJ; Ekinci EI; Jerums G
    Am J Kidney Dis; 2014 Feb; 63(2 Suppl 2):S39-62. PubMed ID: 24461729
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acylcarnitines: Can They Be Biomarkers of Diabetic Nephropathy?
    Mu X; Yang M; Ling P; Wu A; Zhou H; Jiang J
    Diabetes Metab Syndr Obes; 2022; 15():247-256. PubMed ID: 35125878
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Urinary mRNA markers of epithelial-mesenchymal transition correlate with progression of diabetic nephropathy.
    Zheng M; Lv LL; Cao YH; Zhang JD; Wu M; Ma KL; Phillips AO; Liu BC
    Clin Endocrinol (Oxf); 2012 May; 76(5):657-64. PubMed ID: 21824169
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Endothelin-1 and endothelin a receptor immunoreactivity is increased in patients with diabetic nephropathy.
    Zanatta CM; Veronese FV; Loreto Mda S; Sortica DA; Carpio VN; Eldeweiss MI; da Silva VD; Lopes TG; Gross JL; Canani LH
    Ren Fail; 2012; 34(3):308-15. PubMed ID: 22250646
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes.
    DiPetrillo K; Coutermarsh B; Gesek FA
    Am J Physiol Renal Physiol; 2003 Jan; 284(1):F113-21. PubMed ID: 12388406
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Searching for novel biomarkers and new therapeutic targets of diabetic nephropathy using proteomics approaches.
    Thongboonkerd V
    Contrib Nephrol; 2008; 160():37-52. PubMed ID: 18401160
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Will the future lie in multitude? A critical appraisal of biomarker panel studies on prediction of diabetic kidney disease progression.
    Schutte E; Gansevoort RT; Benner J; Lutgers HL; Lambers Heerspink HJ
    Nephrol Dial Transplant; 2015 Aug; 30 Suppl 4():iv96-104. PubMed ID: 26209744
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biomarkers of diabetic kidney disease.
    Colhoun HM; Marcovecchio ML
    Diabetologia; 2018 May; 61(5):996-1011. PubMed ID: 29520581
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Proteomics and diabetic nephropathy: what have we learned from a decade of clinical proteomics studies?
    Papale M; Di Paolo S; Vocino G; Rocchetti MT; Gesualdo L
    J Nephrol; 2014 Jun; 27(3):221-8. PubMed ID: 24567069
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diabetic nephropathy: is it always there? Assumptions, weaknesses and pitfalls in the diagnosis.
    Ioannou K
    Hormones (Athens); 2017 Oct; 16(4):351-361. PubMed ID: 29518755
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Systems Biology Overview on Human Diabetic Nephropathy: From Genetic Susceptibility to Post-Transcriptional and Post-Translational Modifications.
    Conserva F; Gesualdo L; Papale M
    J Diabetes Res; 2016; 2016():7934504. PubMed ID: 26798653
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Early urinary biomarkers of diabetic nephropathy in type 1 diabetes mellitus show involvement of kallikrein-kinin system.
    Vitova L; Tuma Z; Moravec J; Kvapil M; Matejovic M; Mares J
    BMC Nephrol; 2017 Mar; 18(1):112. PubMed ID: 28359252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.